Clinical trials: Acute Phase
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
Nasal Congestion and Inflammations, Rhinitis
Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion…
- Trial name
- NCT01393548
- Testing
- brompheniramine + phenylephrine, Brompheniramine + pseudoephedrine
- Where
- Brazil
- Volunteers
- 879 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- Trial name
- NCT05143996
- Testing
- CLN-049
- Where
- 17 sites in United States
- Volunteers
- 275 people
- Sponsor
- Cullinan Therapeutics Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
This study will take place in parts: Dose Escalation (Part 1): Participants receive milademetan alone with different dose schedules Dose Escalation (Part 1A): Participants receive milademetan in combination with 5-azacytidine…
- Trial name
- NCT02319369
- Testing
- Milademetan, AZA
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Daiichi Sankyo
Leukemia, Myeloid, Acute
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
This study is a randomized, multicenter, open-label, Phase 2 study that will be run in 2 parts: a safety run-in part to determine the dose of azacitidine and then a second part to determine the efficacy of that dose in children…
- Trial name
- NCT02450877
- Testing
- Azacitidine, Control Arm
- Where
- 8 sites in Denmark, Germany and 1 more
- Volunteers
- 7 people
- Sponsor
- Celgene
Acute Gastrointestinal Graft vs Host Disease
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- SUPPORTS (NCT00926575)
- Testing
- oral beclomethasone 17,21-dipropionate
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Soligenix
Acute Myeloid Leukemia
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
This Phase I study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are…
- Trial name
- NCT03564288
- Testing
- SKI-G-801
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Oscotec Inc.
Acute Myeloid Leukemia
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Phase I, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms with IDH1 and/or IDH2 Mutation.
- Trial name
- NCT04272957
- Testing
- HMPL-306
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hutchison Medipharma Limited
Respiratory Syncytial Virus Infection
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
- Trial name
- NCT06904222
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Acute Infectious Keratoconjunctivitis
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK).
- Trial name
- NCT05636228
- Testing
- INV-102, Vehicle
- Where
- 12 sites in United States, Thailand
- Volunteers
- 93 people
- Sponsor
- Invirsa, Inc.
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Leukemia, Myeloid, Acute
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
- Trial name
- NCT01390337
- Testing
- AC220, daunorubicin, cytarabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia
The primary objective is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid leukemia (AML).
- Trial name
- NCT00279773
- Testing
- TKI258
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Acute Bronchitis
A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Umkamin tab.
- Trial name
- NCT03654196
- Testing
- HL301(Experimental), Umkamin(Active Comparator)
- Where
- South Korea
- Volunteers
- 246 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Acute Lymphoblastic Leukemia
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
- Trial name
- NCT05223686
- Testing
- Human CD19-CD22 Targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Chronic Kidney Diseases
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
This parallel-group, randomized, placebo-controlled study will examine the incidence and severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage III/IV following an i.v.
- Trial name
- NCT03119662
- Testing
- Visipaque
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Schizophrenia
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
- Trial name
- NCT05011669
- Testing
- Lurasidone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.